Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Financial Results (May 6, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 6, 2025
Period End
May 6, 2025
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed May 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported financial results for the first quarter ended March 31, 2025, and raised its 2025 financial guidance ranges, as furnished in Exhibit 99.1 under Item 2.02.

Total revenue was $264.9 milliona, up 35% year over year from $195.9 million, driven by royalty revenue of $168.2 million, up 39% from $120.6 million. Net income was $118.1 million versus $76.8 million, GAAP diluted EPS was $0.93 versus $0.60, and non-GAAP diluted EPS was $1.11 versus $0.79. Adjusted EBITDA was $162.0 million versus $115.7 million in the prior-year quarter.

The company raised full-year 2025 guidance: total revenue of $1,200 million to $1,280 millionb (previously $1,150 million to $1,225 million), royalty revenue of $750 million to $785 million (previously $725 million to $750 million), adjusted EBITDA of $790 million to $840 million (previously $755 million to $805 million), and non-GAAP diluted EPS of $5.30 to $5.70 (previously $4.95 to $5.35). The guidance reflects tariffs currently implemented. The company also announced a second $250 million share repurchase under its $750 million program approved in February 2024, following the first $250 million accelerated share repurchase completed in March 2025.

Cash, cash equivalents and marketable securities were $747.9 millionc at March 31, 2025. The filing also disclosed an April 2025 patent infringement lawsuit against Merck Sharp & Dohme Corp. in the U.S. District Court in New Jersey, alleging that Merck is using Halozyme's MDASE technology to develop subcutaneous Keytruda, and seeking damages and injunctive relief. Partner activity included several ENHANZE-related regulatory and commercial milestones, including FDA approval of VYVGART Hytrulo prefilled syringe for self-injection and a European Commission marketing authorization for SC RYBREVANT with ENHANZE, described as the 10th partner product with ENHANZE to be commercialized.

Key Highlights

  1. Total revenue of $264.9 million in Q1 2025, up 35% year over year from $195.9 million, primarily driven by royalty revenue growth and higher bulk rHuPH20 sales.
  2. Royalty revenue of $168.2 million, up 39% from $120.6 million, attributed mainly to VYVGART Hytrulo, DARZALEX SC and Phesgo.
  3. Net income of $118.1 million versus $76.8 million; GAAP diluted EPS of $0.93 versus $0.60; non-GAAP diluted EPS of $1.11 versus $0.79.
  4. Adjusted EBITDA of $162.0 million, compared with $115.7 million in Q1 2024.
  5. 2025 guidance raised: total revenue to $1,200–$1,280 million, royalty revenue to $750–$785 million, adjusted EBITDA to $790–$840 million, and non-GAAP diluted EPS to $5.30–$5.70.
  6. Announced a second $250 million share repurchase under the $750 million program approved in February 2024, after completing the first $250 million accelerated share repurchase in March 2025.
  7. Filed a patent infringement lawsuit against Merck in April 2025 over alleged use of MDASE technology in subcutaneous Keytruda development.

Frequently Asked Questions

  1. How did Halozyme perform financially in the first quarter of 2025?

    Total revenue rose 35% year over year to $264.9 million, and net income increased to $118.1 million from $76.8 million. GAAP diluted EPS was $0.93 versus $0.60, and non-GAAP diluted EPS was $1.11 versus $0.79. Operating income was $141.5 million compared with $95.5 million a year earlier.

  2. What changed in Halozyme's 2025 financial guidance?

    The company raised total revenue guidance to $1,200–$1,280 million from $1,150–$1,225 million, royalty revenue to $750–$785 million from $725–$750 million, adjusted EBITDA to $790–$840 million from $755–$805 million, and non-GAAP diluted EPS to $5.30–$5.70 from $4.95–$5.35. The guidance reflects tariffs currently implemented and does not consider potential future share repurchases for EPS purposes.

  3. What is the status of Halozyme's share repurchase program?

    The company completed a first $250 million accelerated share repurchase in March 2025 under a $750 million program approved in February 2024, and announced a second $250 million repurchase on May 6, 2025.

  4. What is the Merck lawsuit about?

    In April 2025, Halozyme sued Merck Sharp & Dohme Corp. in the U.S. District Court in New Jersey, alleging Merck is using Halozyme's patented MDASE subcutaneous drug delivery technology to develop subcutaneous Keytruda. Halozyme seeks damages and injunctive relief.

  5. What was the company's cash position at the end of the quarter?

    Cash, cash equivalents and marketable securities totaled $747.9 million on March 31, 2025, up from $596.1 million on December 31, 2024, primarily due to cash generated from operations.